Chemistry:LY294002
| |
| Names | |
|---|---|
| Preferred IUPAC name
2-(Morpholin-4-yl)-8-phenyl-4H-1-benzopyran-4-one | |
| Other names
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C19H17NO3 | |
| Molar mass | 307.349 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
LY294002 is a morpholine-containing chemical compound that is a potent inhibitor of numerous proteins, and a strong inhibitor of phosphoinositide 3-kinases (PI3Ks).[1] It is generally considered a non-selective research tool, and should not be used for experiments aiming to target PI3K uniquely.[2]
Two of these are the proto-oncogene serine/threonine-protein kinase (PIM1) and the phosphatidylinositol-4,5-bisphosphate 3-kinase P110 gamma|catalytic subunit gamma isoform.[3] With an IC50 of 1.4 μM it is somewhat less potent than wortmannin, another well-known PI3 kinase inhibitor. However, LY294002 is a reversible inhibitor of PI3K whereas wortmannin acts irreversibly.[4]
Application of LY294002 causes a substantial acceleration of MEPP frequency (150 μM) at the frog neuromuscular junction through a mechanism that is independent of intraterminal calcium. LY294002 causes the release of MEPPs through a perturbation of synaptotagmin function.[5]
LY294002 is also a BET inhibitor (e.g. of BRD2, BRD3, and BRD4).[6]
Application
Research
It has been shown that LY294002 administration has an additive effect on quercetin antiviral activity against hepatitis C virus.[7]
References
- ↑ Maira (2009). "PI3K inhibitors for cancer treatment: where do we stand?". Biochemical Society Transactions 37 (Pt 1): 265–272. doi:10.1042/BST0370265. PMID 19143644.
- ↑ Arrowsmith, Cheryl H.; Audia, James E.; Austin, Christopher; Baell, Jonathan; Bennett, Jonathan; Blagg, Julian; Bountra, Chas; Brennan, Paul E. et al. (2015-08-01). "The promise and peril of chemical probes". Nature Chemical Biology 11 (8): 536–541. doi:10.1038/nchembio.1867. ISSN 1552-4450. PMID 26196764.
- ↑ "Card for LY294002 in DrugBank". DrugBank. http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB02656.txt. Retrieved 2009-09-25.
- ↑ Chris J. Vlahos (1994). "A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (LY294002)". Journal of Biological Chemistry 269 (7): 5241–5248. doi:10.1016/S0021-9258(17)37680-9. PMID 8106507. http://www.jbc.org/content/269/7/5241.full.pdf+html.
- ↑ "LY 294002 inhibits adenosine receptor activation by a mechanism independent of effects on PI-3 kinase or casein kinase II". Purinergic Signal. 1 (4): 389–94. Dec 2005. doi:10.1007/s11302-005-0778-6. PMID 18404524.
- ↑ Dittmann, Antje; Werner, Thilo; Chung, Chun-Wa; Savitski, Mikhail M.; Fälth Savitski, Maria; Grandi, Paola; Hopf, Carsten; Lindon, Matthew et al. (2013). "The Commonly Used PI3-Kinase Probe LY294002 is an Inhibitor of BET Bromodomains". ACS Chemical Biology 9 (2): 495–502. doi:10.1021/cb400789e. PMID 24533473. https://zenodo.org/record/3424141.
- ↑ Pisonero-Vaquero S (Mar 2014). "Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin.". Lab. Invest. 94 (3): 262–274. doi:10.1038/labinvest.2013.156. PMID 24492281.
 |  |
